Trial Profile
Phase I Clinical Trial of M6620 (VX-970, Berzosertib) in Combination With the Topoisomerase I Inhibitor Irinotecan in Patients With Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Berzosertib (Primary) ; Irinotecan (Primary)
- Indications Carcinoma; Colorectal cancer; Lung cancer; Non-small cell lung cancer; Pancreatic cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions
- 07 Dec 2023 Planned End Date changed from 30 Apr 2024 to 5 Dec 2024.
- 02 May 2023 Planned End Date changed from 30 Apr 2023 to 30 Apr 2024.
- 02 May 2023 Planned primary completion date changed from 30 Apr 2023 to 30 Apr 2024.